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Coronary artery disease (CAD) has a strong genetic predisposition. However, despite 
substantial discoveries made by genome-wide association studies (GWAS), a large proportion 
of heritability awaits identification. Non-additive genetic-effects might be responsible for part 
of the unaccounted genetic variance. Here we attempted a proof-of-concept study to identify 
non-additive genetic effects, namely epistatic interactions, associated with CAD.  
 
Methods and Results: 
We tested for epistatic interactions in ten CAD case-control studies and UK Biobank with focus 
on 8,068 SNPs at 56 loci with known associations with CAD risk. We identified a SNP pair 
located in cis at the LPA locus, rs1800769 and rs9458001, to be jointly associated with risk for 
CAD (odds ratio [OR]=1.37, p=1.07×10-11), peripheral arterial disease (OR=1.22, p=2.32×10-
4), aortic stenosis (OR=1.47, p=6.95×10-7), hepatic lipoprotein(a) (Lp(a)) transcript levels 
(beta=0.39,p=1.41×10-8), and Lp(a) serum levels (beta=0.58, p=8.7×10-32), while individual 
SNPs displayed no association. Further exploration of the LPA locus revealed a strong 
dependency of these associations on a rare variant, rs140570886, that was previously associated 
with Lp(a) levels. We confirmed increased CAD risk for heterozygous (relative OR=1.46, 
p=9.97×10-32) and individuals homozygous for the minor allele (relative OR=1.77, p=0.09) of 
rs140570886. Using forward model selection, we also show that epistatic interactions between 
rs140570886, rs9458001, and rs1800769 modulate the effects of the rs140570886 risk allele. 
 
Conclusions:  
These results demonstrate the feasibility of a large-scale knowledge-based epistasis scan and 
provide rare evidence of an epistatic interaction in a complex human disease. We were directed 
to a variant (rs140570886) influencing risk through additive genetic as well as epistatic effects. 
In summary, this study provides deeper insights into the genetic architecture of a locus 
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Translational Perspective:  
Genetic variants identified by GWAS studies explain about a quarter of the heritability of 
coronary artery disease by additive genetic effects. Our study demonstrates that non-additive 
effects contribute to the genetic architecture of the disease as well and identifies complex 
interaction patterns at the LPA locus, which affect LPA expression, Lp(a) plasma levels and 
risk of atherosclerosis. This proof-of-concept study encourages systematic searches for epistatic 












Coronary artery disease (CAD) is one of the largest contributors to morbidity and mortality 
worldwide1. A fundamental aspect of CAD is its complex and multifactorial aetiology, which 
includes numerous environmental risk factors, such as obesity and smoking2, as well as a strong 
genetic predisposition. Overall, the genetic variance is estimated to explain 40-50% of the 
variability in disease manifestation3. 
 
A decade of genome-wide association studies (GWAS) shed light on the genetic architecture 
of the disease, discovering 163 genetic loci associated with CAD risk4,5. About a quarter of 
CAD heritability can be explained by additive effects of these and other common genetic 
variants4,5. More complex models involving gene regulatory networks6 may help to better 
explain the heritability of the disease. In addition, at some of these loci, multiple independent 
signals were described, showing intra-locus allelic heterogeneity7. Until now non-additive 
genetic effects, such as epistatic interactions, are largely neglected for explaining the 
heritability of CAD. However, epistasis has been postulated by some to account for part of this 
“missing heritability”8 and has also been found to act alongside additive effects to influence 
complex phenotypes.9,10 
 
Epistatic interactions have profound effects in bacteria11 as well as in other higher model 
organisms12 and have been shown to regulate some quantitative traits in humans13. However, 
evidence of epistasis in human genetics remains very scarce, because individual-level data with 
large sample sizes are required for epistasis studies. Moreover, the combinatorial nature of 
epistasis makes hypothesis-free genome-wide interaction analyses (GWIAs) computationally 
demanding and plagued with a high multiple testing burden. Finally, associations based on 
interactions appear to suffer from a low replication rate14 and genetic interactions are sometimes 
difficult to disentangle from the tagging of haplotypes15. Indeed, a non-causal combination of 
alleles at multiple SNPs co-inherited with a rare causal variant could act as a tag for this variant.    
 
To face the computational complexities in search for interacting loci affecting risk for CAD, 
we conducted a two-stage statistical scanning procedure for epistasis using a GPU-accelerated 
software16 on individual level data from several GWAS on CAD. The scan was based on 
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3.1.1 CAD case-control studies  
Individual-level genotypes were obtained from ten CAD case-control studies. From Germany: 
the German Myocardial Infarction Family Studies (GerMIFS) I17, II18, III (KORA)19, IV20, V21, 
VI22; the LUdwigshafen RIsk and Cardiovascular Health Study (LURIC)23; from Germany, 
England, and France: Cardiogenics; from England: Wellcome Trust Case Control Consortium 
(WTCCC)24,25; from France, Italy, Germany, and the United States: Myocardial Infarction 
Genetics Consortium (MIGen)25,26. Data from the WTCCC were obtained via the Leducq 
network “CADgenomics” (https://www.fondationleducq.org/network/understanding-
coronary-artery-disease- genes/). MIGen data were obtained via the database of Genotypes And 
Phenotypes (dbGaP; project ID #49717-3)27. The genotype processing procedures including 
QC and imputation are provided in the Supplementary Methods. The final sample sizes for each 
study after QC are listed in Supplementary Table 1. All participants were of European origin 
and gave prior written informed consent, which specifically addressed that the materials will 
be used for genetic studies. All studies obtained institutional review board approval from their 
local Ethical Committees and were performed in accordance with the 1964 Helsinki Declaration 
and its later amendments. Ascertainment and assessment methods for CAD of each study are 
provided in the corresponding publications.  
 
3.1.2 UK Biobank  
The UK Biobank (UKBB) project (http://www.ukbiobank.ac.uk) is a large prospective cohort 
study of ~500,000 individuals from across the United Kingdom, aged 40-69 years at 
recruitment28. In the present study, CAD cases were defined using the “SOFT” and “HARD” 
criteria22, i.e., as individuals with fatal or nonfatal myocardial infarction (MI), percutaneous 
transluminal coronary angioplasty (PTCA), coronary artery bypass grafting (CABG), chronic 
ischemic heart disease (IHD) and angina. Peripheral arterial disease (PAD) cases were defined 
as self-reported history of PAD, leg claudication / intermittent claudication, or either 
hospitalization or death due to ICD9-443.9, ICD9-444, ICD10-I73.9, or ICD10-I74. Aortic 
valve stenosis cases were defined as a self-reported history of aortic stenosis, or either 






/cardiovascres/advance-article/doi/10.1093/cvr/cvab136/6240984 by guest on 12 M
ay 2021
 8 
control (QC) performed in the UKBB dataset is detailed in the Supplementary Methods. UKBB 
data were accessed under approval of UKBB within project 9922. The study was conducted 
following the principles of the declaration of Helsinki and all participants gave prior written 
informed consent. 
3.1.3 KORA F3/F4 studies and STARNET-Study: 
Individual-level genotypes were obtained from population studies from Augsburg, Germany29: 
KORA F3 and KORA F430,31 along with lipid measurements including total lipoprotein(a) 
[Lp(a)] levels and the number of Kringle repeats of the Lp(a) protein. RNAseq data were 
generated from liver tissue of 522 CABG CAD patients from the Stockholm-Tartu Reverse 
Network Engineering Task (STARNET) study32. These studies obtained institutional review 
board approval from their local Ethical Committees and were performed in accordance with the 
1964 Helsinki Declaration and its later amendments. All participants gave prior written 
informed consent. Further information about these studies are provided in the Supplementary 
Methods.  
3.2 Epistasis scan 
3.2.1 Broad Sense CAD susceptibility region 
We focused our analysis on 56 loci with previous evidence from GWAS on CAD20,25 
(Supplementary Table 14) in order to restrict the number of variants for testing of statistical 
epistasis. Our aim was to enhance computation time and the likelihood of true positive findings 
by easing the multiple testing correction burden. CAD susceptibility regions were defined as 
±500kb around each of the 56 lead SNPs20,25. This window size was chosen to capture the loci 
as completely as possible while minimizing the computational burden: The variance explained 
by the lead SNPs accounted for only 46% of the variance explained when including their 
flanking ±500kb regions (Supplementary figure 2, Supplementary Methods). We then pruned 
the variants in each region to 8,068 SNPs with pairwise r2<0.5 located in the broad CAD 
susceptibility regions.  
3.2.2 Statistical interaction analysis  
We used the general framework for detecting statistical epistasis in quantitative genetics as 
proposed by Hansen and Wagner33 on the pairwise epistasis between two loci (SNPs) and 
implemented a two-stage statistical scanning procedure (Figure 1). The first step of the testing 
procedure consisted in a loose but fast statistical filtering using the GLIDE GPU computation 
tool16. For each possible pair of SNPs, we fitted a linear model with the CAD phenotype as the 
dependent variable and the marginal effect of the two SNPs and their interaction term as 
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dominant, recessive and heterozygous with respect to the minor allele and all combinations of 
















2   
(1) 
A relatively loose and arbitrary significance level (p < 1×10-8) was applied for primary filtering, 
with the assumption that if true epistasis existed between two SNPs, signals of moderate 
strength should be detectable between the SNPs within the corresponding linkage 
disequilibrium (LD) block. This threshold was defined with the aim to detect such pair in LD 
with the true epistasis signal and to forward a manageable number of pairs to the second step.  
 
The second step included the fine-mapping of candidate SNP pairs to screen for the strongest 
signal among the SNPs in the same LD block. For this purpose, we used R to fit a logistic 
regression model, slower than the linear model used in step 1, but suited better for the binary 
CAD phenotype, and extended Eq(1) to correct for population structure by adding the first ten 
multidimensional scaling (MDS) components of the genetic relationship matrix (designated as 
MDS1..10 in Eq(2) and following equations).In this second step, we applied a stringent 
significance threshold of 4.6×10-9 , calculated as a Bonferroni correction (0.05 ⁄ (nSNP_indep × 
(nSNP_indep - 1) / 2) = 4.6178e-9 ) on the number of LD independent SNPs resulting from step 1 
(nSNP_indep = 4,654). Each SNP pair was encoded in the genetic model displaying the highest 






























In the discovery phase, the same epistasis testing procedure was performed in each of the ten 
CAD case-control studies separately. The models used genotype data imputed to the 1000 
Genomes Phase 3 (1000GP3) reference panel. This regression analysis was followed by fixed-
effects meta-analysis to estimate the overall effect size and standard error. The final epistasis 
pair of interest was then reanalysed in the same studies imputed using the Haplotype Reference 
Consortium (HRC) reference panel, to enable a more complete coverage of the region of interest 
in all ten cohorts. Thereafter, this imputation based on the larger HRC reference was used for 
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3.2.3 Prioritizing candidate SNP pairs of epistasis of CAD  
After the detection of SNP pairs showing statistically significant epistatic effects on the risk for 
CAD, we prioritized candidate pairs based on the following four criteria: 
1) We retained only SNP pairs with a high replication potential (i.e., displaying statistical 
epistasis both significantly (p<4.6×10-9) and consistently (effect sizes pointing in the 
same direction) in at least eight of the ten studies in the discovery data, based on both 
imputations). 
2) LD between two target SNPs located on the same chromosome r2<0.2. 
3) Weak interaction signals detectable between SNPs that show an LD r2> 0.5 with any of 
the two interacting SNPs. 
4) The effect of the interaction term is independent (i.e., p-value in conditional models 
<7.8×10-6) of any available third variant in conditional analyses. 
3.3 Conditional analysis 
The aim of the conditional analysis was to test whether the statistical epistasis effects were 
independent from a third SNP. To this end, we tested for the independence of the interaction 
term against the SNPs located within a ±200kb window around the epistatic loci and any known 
CAD GWAS SNPs that survived the original QC procedure. This window size was chosen to 
capture all SNPs in significant LD with the pair of interest. Indeed, it has been shown that LD 
decay with physical distance and is close to 0 at 200kb34,35.  For each of these SNPs, we used 
R to compute a likelihood ratio test (LRT) between a model including the additive effect of the 
two target SNPs and the additive effect of the conditioning SNP [all coded as minor allele 






























































The interaction term was considered dependent on the conditioning SNP if the LRT did not 
reach a Bonferroni-corrected significance threshold defined on the total number of conditioning 
SNPs. This analysis was performed on a merged dataset of the ten CAD studies. Here, the MDS 
components of the genetic relationship matrix used as covariates were re-calculated on the 
merged dataset.  
3.4 Relative effect sizes and analyses of intermediate traits  
Genotypic effect sizes for the different rs140570886 genotypes were computed by regression 
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intermediate traits Lp(a) protein levels, LPA mRNA levels and KIV repeats were also 
performed using linear regression. Lp(a) proteins levels were highly skewed and Inverse 
Normal Transformation was applied prior association. Relative effect size for the three-SNP 
haplotypes were computed via haplotype estimation followed by fitting a generalized linear 
model with the R package happassoc. More detailed descriptions of these statistical procedures 
are provided in the Supplementary methods. 
4 Results 
4.1 Discovery of SNP pairs associated with CAD risk 
We identified 56 previously known CAD risk loci from two previous GWAS20,25 
(Supplementaty Table 14). For our study, we extracted 8,068 LD-independent candidate 
variants within 500kb of the respective lead SNPs. We observed that these extended regions 
explained more phenotypic variance than the respective lead SNPs alone (Supplementary Fig 
2, Supplementary Methods). Testing for statistical interactions was carried out on all pairwise 
SNPs along a two-step scheme (described in Figure 1) on imputed genotypes from 29,755 
participants of ten European CAD case-controls studies17–22,24–26 (Figure 2). Four SNP pairs 
displayed consistent (i.e., in at least eight of ten studies) and significant (i.e, p ≤ 4.618×10-9) 
effects and thus met our criteria as candidates for epistasis (Supplementary Table 2). Among 
these four pairs, two (rs1800769×rs9458001 and rs116632378× rs3823438) did replicate in the 
UKBB.  The top SNP pair (rs1800769×rs9458001) showed the strongest effect in a dosage-
dosage model and was prioritized for further investigation (Supplementary Table 3).  
Both rs1800769 and rs9458001 map to chromosome 6, close to the LPA locus (Figure 3b), and 
are not in LD with each other (r2=0.014, D=0.535, Table 1). None of the SNPs were associated 
with CAD risk by itself in an additive model (p=0.59, odds ratio [OR]=0.99 for rs1800769[T]; 
p=0.08, OR=1.04 for rs9458001[A], Supplementary Table 2). However, the interaction term 
displayed a strong association (ORint=1.42, p=1.75×10
-13 for the rs1800769[T] ×rs9458001[A] 
interaction term). In this case, as both SNP were encoded in the additive genetic model, the OR 
can be interpreted as the increase in likeliness to suffer from CAD associated with an increase 
of one unit in the product between the number of minor alleles at each of the interacting SNPs. 
The results were reproduced in the same dataset imputed with the HRC reference panel36 using 
rs1652507 (LD with rs1800769, r2=0.965, D’=0.991, Table 1) as a proxy for rs1800769 (odds 
ratio (OR)=0.98 , p=0.38 for rs1652507[C]; OR=1.03, p=0.1 for rs9458001[A], and ORint=1.36, 
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Thus, the results were qualitatively independent of the imputation panel. This newer and denser 
imputation with this proxy variant was used for the remainder of the manuscript.  
4.2 Replication and association with further traits  
The UKBB dataset (controls/cases n=285520/26792), used as an external replication sample 
(Figure 2), showed a consistent interaction effect of this SNP pair for CAD (ORint=1.15, 
p=5.67×10-10 for the rs1652507 [C]×rs9458001[A] interaction term with the SNPs encoded in 
the dosage model, Supplementary Table 8). Moreover, we found interaction effects in the same 
direction and with a comparable magnitude on peripheral vascular disease (controls/cases 
n=475,059/4,460, ORint=1.22, p=2.32×10
-4) and aortic valve stenosis (controls/cases 
n=477,496/2,023, ORint=1.47, p=6.95×10
-7) (Supplementary Table 8), conditions known to be 
affected by Lp(a) plasma levels37,38. 
Next, we analysed the influence of the interaction term rs1800769×rs9458001 on circulating 
Lp(a) levels in a German population-based study (KORA F3/F430,31 n=5,953) (Figure 2). In 
addition to the association of each SNP separately, we identified a strong interaction effect of 
both SNPs on inverse-rank normal-transformed (INT) Lp(a) levels (beta=0.58, p=8.7×10-32, 
with the SNP encoded in the dosage model, Supplementary Table 6). In the LURIC study, we 
replicated the significant statistical interaction for INT Lp(a) levels (beta=0.56, p=6.93×10-16) 
and found no other circulating factor displaying such effects (data not shown).  
Finally, we extended our investigation to LPA mRNA expression in liver tissue (Methods, 
STARNET study, n=522) (Figure 2), where LPA is transcribed into Apo(a) and further 
assembled with an LDL-like particle into Lp(a). A significant interaction between the two SNPs 
was found (p=1.4×10-8) and the effects on LPA mRNA expression correlated with the 
circulating Lp(a) levels measured in KORA F3/F4 for various genotype subgroups 
(Supplementary Table 6), suggesting that differential gene expression activity underlies a large 
component of statistical interaction related to the two SNPs.  
4.3 rs140570886-related effects at the LPA locus  
An inherent challenge in testing for epistasis of nearby SNPs, even if they are in very low LD, 
is to discriminate interacting SNPs from SNPs representing a specific haplotype. In order to 
explore the latter possibility, we assessed the interaction effect after conditioning for any known 
susceptibility SNPs for CAD (n=158, Supplementary table 4) or any available SNP in the 
flanking ±200kb region. The LPA region conditional analysis (see Methods) did not yield any 
significant results (Supplementary Table 5). However, studying GWAS lead SNPs 
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rs1652507×rs9458001 interaction term (increase from p=1.07×10-11 to p=2.08×10-5, likelihood 
ratio test).  
In follow-up analyses, we also analysed the influence of the rare variant rs140570886 at the 
LPA locus, previously shown to be univariately associated with Lp(a) levels39. This variant was 
not included in our primary analysis because its minor allele frequency was lower than our QC 
threshold (see Methods), but was pointed out to us as requiring special attention. We therefore 
specifically investigated rs140570886 in the conditional analysis and observed a drastic 
decrease in the statistical support for the rs1652507×rs9458001 interaction term (from 
P=8.95×10-14 to p=0.022, likelihood ratio test). In order to test if these two SNPs (LD between 
rs140570886 and rs3798220: r2=0.808, D’=0.899) represented independent signals, we 
performed model selection using the likelihood ratio test. Adding rs3798220 to a model already 
containing rs140570886 did not improve the fit significantly (p=0.49, likelihood ratio test). We 
therefore conclude that rs3798220 is not independent of rs140570886 and did not assess this 
SNP in further analyses.  
We next investigated the additive effect of rs140570886 on CAD risk and found a significant 
association (OR=1.98, p=1.14×10-21,  Figure 3A, Supplementary Table 10). We replicated this 
association in the UKBB dataset (OR=1.46, p=2.77×10-32) (Figure 3A). Furthermore, In the 
UKBB, we found an association in the same direction and comparable magnitude for peripheral 
arterial disease (controls/cases n=315072/29877, OR=1.43,p=7.83×10-6) and aortic valve 
stenosis (controls/cases n=315072/29877, OR=1.71,p=1.25×10-7) (Supplementary Table 10), 
both of which are manifestations of atherosclerosis in coronary arteries for which Lp(a) plasma 
levels affect risk37,38.   
 
To assess the contribution of rs140570886 genotypes to disease risk beyond the additive model, 
we next computed genotypic ORs for heterozygous [T/C] and minor allele homozygous 
genotypes [C/C] compared to the major allele homozygous reference genotype [T/T]. The 
genotypic model has the advantage that it does not make any assumption on the underlying 
genetic model. In the meta-analysis of the ten CAD studies, we observed an OR of 1.88 
(P=2.32×10-18) for the T/C heterozygous genotype (Figure 4 A, Supplementary Table 10). A 
reliable effect estimate could not be calculated for the minor allele homozygous genotype C/C, 
due to its low frequency. The result for the T/C genotype was replicated in UKBB (OR=1.46, 
p=9.97×10-32) where we observed a trend for a higher relative OR for CC-homozygous subjects, 
although this was non-significant, likely due to its low frequency (OR=1.77, p=0.09; Figure 4 
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additive genetic model is indeed likely correct for rs140570886. Coherent with this, the 
saturated genotypic model does not provide a better fit than the additive model (p=0.12, 
likelihood ratio test). We also observed a strong association of rs140570886 with Lp(a) levels 
(beta=1.54, p=9.52×10-82). As was the case for CAD risk, analyses of genotypic models 
indicated a linear increase with the minor allele count and thus supported an additive model 
(Figure 4 C).  
 
Circulating Lp(a) levels are modulated by at least two independent mechanisms40. First, they 
are inversely correlated with the number of Kringle IV type 2 repeats (KIV-2 CNV)41,42, with 
fewer KIV-2 CNV repeats associated with more Lp(a) release from liver cells43. They account 
for about 18% of the variability in Lp(a) levels in Western Europeans44. However, individuals 
with the same number of KIV-2 CNV repeats may still differ up to 200-fold with respect to 
their Lp(a) levels41,42, suggesting transcriptional mechanisms. In the KORA cohorts, we 
observed an association of rs140570886 with the KIV-2 CNV, with heterozygous rs140570886 
carriers having fewer KIV-2 CNV repeats (beta=-5.74, p=3.55×10-26) (Supplementary Table 
10, Supplementary Methods). However, rs140570886 was in minimal LD with the reported 61 
KIV-2 CNV-representing variants and the three independent modifier variants that influence 
the relationship between KIV-2 CNV and Lp(a) cholesterol44 (data not shown). More 
importantly, the effect of rs140570886 on Lp(a) levels remained highly significant after 
adjustment for the KIV-2 CNV (beta=1.11, p=1.94×10-57) (Figure 4 C, Supplementary Table 
10). This strongly suggests that the effect of rs140570886 on Lp(a) levels is independent of the 
KIV-2 CNV and might therefore be modulated by transcriptional regulation. In accordance with 
this hypothesis, we found rs140570886 to be part of a significant expression quantitative trait 
locus (eQTL) with LPA mRNA expression levels in liver tissue, where LPA is transcribed to 
Apo(a) and further assembled into Lp(a) (GTEx V8, normalized effect size =0.98, p=1.2×10-
7).  
4.4 Interaction between rs140570886 and the rs1652507-rs9458001 pair 
Although it appeared that part of the rs1652507×rs9458001 interaction was due to tagging of a 
rs140570886-related effect, we wondered if epistasis could still be present. To investigate this 
possibility, we applied a likelihood ratio tests-based forward model selection procedure starting 
with only rs140570886 going up to a model including all main effects and interactions between 
the four SNPs, rs1652507, rs9458001, rs140570886, and rs3798220 (Supplementary Methods, 
Table 2). To increase statistical power, we here analyzed the ten CAD studies and UKBB 
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added as predictors to the model already containing rs140570886. The addition of the 
rs1652507×rs9458001 interaction term to this second model did not improve the fit further, 
coherent with the observed drop in the significance when conditioning the model containing 
the interaction term on rs140570886. However, the model fit increased significantly and 
reached its best level when all two-way and three-way interactions were added to the model. 
The direct comparison of this two-and-three-way interaction model to the rs140570886-only 
model yielded a p-value of the same magnitude as the original p-value threshold used for the 
epistasis screening (p=6.46×10-9). Using a type-III Sum of Squares Anova to dissect this final 
model, provided further insights into the importance of the different coefficients 
(Supplementary Table 12): We observed in the two-and-three-way interactions model that the 
additive effect of rs140570886 became non-significant while the additive effect of rs1652507 
reached significance. Moreover, albeit the originally discovered rs1652507×rs9458001 
interaction term became non-significant, we observed nominally significant interactions of both 
rs1652507 and rs9458001 with rs140570886. These results suggest that the additive effect of 
rs140570886 on CAD risk might actually be caused by more complicated patterns of cis-
epistatic interactions.  
 
To better understand the genetics underlying this statistical model, we computed the relative 
OR for each of the eight possible haplotypes. It appeared that all haplotypes including the major 
T allele for rs140570886 showed similar ORs. Interestingly, we observed that the effect size 
varied profoundly across haplotypes containing the rs140570886 minor allele C, depending on 
the rs1652507 genotype (red vs. blue on Figure 5, Supplementary Table 13). Moreover, for the 
haplotype rs140570886[C] – rs1652507[T], we observed that the ORs were much lower for the 
[A] as compared to the [G] allele at rs9458001, although the standard errors were large due to 
the low frequencies of rarer haplotypes (Figure 5, Supplementary Table 13).  These two 
observations reflect the marginally significant interaction coefficients between rs140570886 
and rs1652507 and between rs140570886 and rs9458001 in the two-and-three-way interaction 
model (Supplementary Table 12). 
 
Finally, in a further attempt to distinguish epistatic interactions involving these three SNPs from 
a haplotype effect, we compared different models containing SNPs encoded in the additive 
model and either haplotypes, interactions, or both, using the Akaike Information Criterion 
(AIC) (Table 3). The model including SNPs and their interactions but no haplotypes showed 
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model fit compared to an additive only model. Secondly, it suggests the presence of a real 
epistatic interaction between the three SNPs rather than an exclusive haplotype effect. The 
likelihood ratio test applied to nested model confirmed this interpretation. Indeed, the most 
complex model, including SNPs, haplotypes and interactions, did not provide a better fit than 
the one without the haplotypes (p=0.26, likelihood ratio test), whereas adding interactions to 
the SNPs model improved the fit significantly (p=0.0034, likelihood ratio test). Although we 
cannot exclude the involvement of other rare or non-typed variants and lack the statistical power 
necessary for these two interactions to reach the significance threshold pre-defined for the scan, 
these results demonstrate a complex genetic architecture involving non-additive and likely 
epistatic effects in the LPA region, underlying the regulation of Lp(a) expression and CAD risk.  
 
5 Discussion 
We report a two-stage testing procedure for epistatic interactions affecting CAD risk. Our 
analysis identified two SNPs at the LPA locus that individually had no effect but jointly 
displayed a strong statistical association with expression of LPA mRNA in liver, Lp(a) levels 
in serum, and with risk for CAD, peripheral arterial disease, and aortic stenosis. Further 
exploration of the locus revealed that parts of these associations were explained by tagging of 
a low-frequency variant (rs140570886), which, in parallel with our study, was found to be 
associated with Lp(a) levels39. In addition, we detected a complex pattern of interactions 
between this variant and two other SNPs in the LPA region. Together, these findings firstly 
provide evidence of epistatic interaction in a complex human disease and provide deeper 
insights into the genetic architecture of an important locus for cardiovascular risk. At the same 
time, these data highlight the challenges in confirming epistatic interactions affecting disease 
risk in humans. 
 
We focused our search for pairwise epistatic interactions on 8,068 SNPs at 56 regions that had 
been found to be associated at genome-wide significance with CAD20,25. Indeed, the selected 
window of LD-pruned SNPs contained 2-fold more information on CAD heritability than the 
respective lead SNPs. Nevertheless, we found only four potentially interacting SNP pairs, 
which highlights the challenge to identify true epistasis modulating a human trait. The top-
ranking interacting pair was located in cis at the LPA locus. Conditional analyses, aiming to 
determine the independence of the epistatic signal between rs1652507 and rs9458001 from 
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strongest epistatic SNP pair tagged a rare genotype with profound effects on the phenotype. 
Further investigation of this variant showed its strong association with CAD and Lp(a) protein 
levels. rs140570886 has been previously associated with cardiovascular disease (CVD) using a 
new integrative framework named FIODOR45. Our result, thus, using a well-established logistic 
regression model45, confirmed the association of rs140570886 with diseases of the 
cardiovascular system. We, moreover, replicated the association of rs140570886 with Lp(a) 
levels reported by Mack et al.39 and identified data collections that indicate an association of 
rs140570886 with CAD46. In addition, we report rs140570886 effects on Lp(a) levels to be 
independent of the KIV CNV repeats and to be a strong eQTL for LPA gene expression. Taken 
together, these findings support the hypothesis that rs140570886 mediates CAD risk through 
the Lp(a) levels via transcriptional regulation.  
 
An important methodological point highlighted by this study is the importance of the 
conditional follow-up analyses in the investigation of epistatic interactions. Indeed, an inherent 
challenge in testing for epistasis of nearby SNPs, even if they are in very low LD, is to 
discriminate truly interacting SNPs from SNPs tagging a specific haplotype47. Resolving the 
dependence structure at the epistatic locus, by conditioning the interaction effect on the 
neighbouring SNPs, allowed us to simultaneously identify a tagged rarer variant and to fine-
map the epistatic interaction at the LPA locus. 
 
The combinatorial nature of interactions has been a major hold-up in epistasis testing because 
it leads to an enormous search space and a high multiple testing correction burden15,48. Methods 
to reduce this space can be divided into two categories: data-driven and knowledge-driven 
methods49. We applied a data-driven approach in the present study, focusing on previously 
associated loci, for two reasons. First, variants already shown to be linked to the disease are 
likely to be functionally important. Second, if epistatic effects were detected among such 
variants, these effects would be more likely to affect the condition. Since regulatory variants 
might be located in the flanking region of the prioritized loci, we extended the search space to 
these regions. The discovery of four pairs of interacting SNPs using this filtering approach 
demonstrates its advantage over a hypothesis-free approach, in which these pairs would not 
have reached statistical significance due to having to correct for more tests. 
 
The findings relative to the genetic architecture of the LPA locus reported in this study carry a 
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have been shown to be usable for CAD risk prediction. For example, the Copenhagen City 
Heart Study showed for individuals above the 95th percentiles of the Lp(a) concentration to 
have a 2.5-fold higher CAD risk compared to individuals in the lowest quartile37. Although 
Lp(a) concentration measurement and isoform determination are sufficient assays to estimate 
CAD risk encoded at the LPA locus50, polygenic risk scores might play an additional role in the 
assessment of CAD risk in the future5. Indeed, with the rapid drop of genotyping cost, 
individual genotype data are becoming a basic component of biobanks and clinical settings51. 
With this perspective, a better understanding of the genetic architecture of the LPA locus and 
the incorporation of non-additive genetic effects, such as those reported in this study, might 
enhance the predictive power of polygenic risk scores and help the development of individually-
tailored disease prevention52, which, in the future, may involve a pharmacological Lp(a) 
reduction53.  
 
While a single epistatic interaction as reported in this manuscript is very unlikely to improve 
risk prediction on its own compared to polygenic risk score based on millions of SNPs, 
numerous interactions – if identified – might do so. Indeed, several observations argue in this 
direction. First, simulations and analyses by others indicate that epistasis cannot be ruled out as 
an important factor10. Particularly, results from the UK Biobank are compatible with an upper 
bound of epistasis explaining slightly more than half as much as additive variance, and a point 
estimate of epistasis explaining a quarter of the amount of variance explained by additively 
acting loci. A further extension of epistasis scans, to testing combinations of variants from 
disease susceptibility regions against the whole genome, or even to genome-wide scans with 
different, a-priori-defined functional, information-based filters, might discover new epistatic 
interactions54, thereby, improving both our understanding of disease aetiology and possibly 
prediction models.  
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12 Figure legends 
Figure 1: Scheme of the two-stage statistical interaction scanning procedure.  
Step 1 aimed at the fast identification of potential significant interaction terms using the GLIDE 
GPU computation tool. For each pair of LD-independent SNPs in the susceptibility regions 
(N=8068 SNPs), we fitted a linear model with the additive and interaction effect of the 2 SNPs 
in each of the 10 CAD studies separately. The 10 p-values were then meta-analysed. A loose 
and arbitrary defined significance level (p < 1e-8) was applied with the assumption that if there 
exists true epistasis between two lead SNPs, loose signals should be detectable between the 
SNPs within the corresponding LD block. Step 2 aimed at validating the results of the first step 
using logistic regression model including the first ten multidimensional scaling (MDS) 
components of the genetic relationship matrix to correct for population structure. Step 2 also 
allowed the fine-mapping of candidate SNP pairs by screening for the strongest signal among 
all the SNPs within the LD blocks forwarded from step 1. In this second step, we applied a 
stringent significance threshold of 4.6×10-9 , calculated as a Bonferroni correction (0.05 ⁄ 
(nSNP_indep × (nSNP_indep - 1) / 2) = 4.6178e-9 ) on the number of LD independent SNPs resulting 
from step 1 (nSNP_indep = 4,654). 
 Figure2: Analysis workflow and datasets. 
Schematic of the analysis workflow.  
A. The epistasis scan was performed as a meta-analysis in the 10 CAD individual GWAS. 
Association of SNP1 (rs1800769) and SNP2 (rs9458001) interaction with CAD was replicated 
in the UK Biobank (UKBB). KORA F3/F4, LURIC and STARNET were used for the 
association analysis of the interacting pair with proximal phenotypes. 
B. The association of the additive effect of rs140570886 with CAD was assessed in a meta-
analysis of the 10 CAD studies and replicated in the UKBB. KORA F3/F4 and GTEx were used 
for the association analysis of with rs140570886 proximal phenotypes. C. The forward model 
selection, the dissection of the best model and the comparison with the haplotypes effect were 
conducted on a merged dataset of the 10 CAD studies and the UKBB in order to achieve higher 
power. The 3-SNP haplotypes analysis on the other hand was carried out on the meta-analysis 
of the 10 CAD studies, because the algorithm used for fitting the Generalized Linear Model 
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Figure 3: The common variant rs140570886, located in the LPA locus, increases CAD risk 
in a meta-analysis of ten CAD studies and replicates in the UK Biobank.  
A. Forest plot displaying the log odds ratio (OR) across 10 studies for rs140570886 as well as 
the fixed meta-analysis (N=29’755)  summary effect (shown as diamond) and the log OR in the 
replication dataset. The effect in the UK BioBank (UKBB, N=312’312) is of the same sign and 
significant, therefore fulfilling the criteria for replication. B. Manhattan plot showing the 
regional signal at the LPA locus taken from a recent genome-wide association study and 
indicating the variants in LD with rs140570886 (red), rs1800769 (blue), rs9458001 (green) and 
rs3798220 (purple). 
 
 Figure 4: Genotype specific effect of rs140570886 on CAD risk and intermediate factors. 
A. Genotypic log odds ratios (OR) (with reference to the genotype [T/T]) for the genotype 
subgroup [T/C] on CAD risk in the meta-analysis of ten CAD studies (N=29’755). The OR for 
the minor allele homozygous genotype (C/C) is not displayed because of its low sample size 
and high standard error. Error bars represents the standard error of the log OR B. Genotypic 
OR (with reference to the genotype [T/T]) for the genotype subgroup [T/C] and [C/C] on CAD 
risk in the UK Biobank dataset (N=312’312). Error bars represents the standard error of the log 
Odds Ratio. C. Relative effect size (with reference to the genotype [T/T]) for the genotype 
subgroup T/C on intermediate factors, namely inverse normal transformed Lp(a) levels (blue), 
KIV size of the dominantly expressed apo(a) isoform (purple) and the inverse normal 
transformed Lp(a) levels independent of the KIV (orange) in the KORA F3/F4 studies 
(N=5953). Relative effect size for the minor allele homozygous genotype (C/C) is not 
displayed, because not represented in the KORA studies. Error bars represent standard error of 
the effect sizes.  
 
Figure 5: Relative effect of the rs140570886- rs1652507- rs9458001 3-SNP haplotypes on 
CAD risk. Relative odds ratio (OR; with reference to the most frequent TTG haplotypes) for 
the 8 possible 3-SNP haplotypes on CAD risk. The red and blue colours represent the base at 
the rs1652507 SNP, the square and triangle shapes represent the base at the rs9458001 SNP 
and the position on the X axis represent the base at the rs140570886 SNP. Together they 
indicate one of the 8 possible 3-SNP haplotypes. The putative haplotypes were computed using 
the happasoc R package on a merged dataset of the 10 CAD studies (N=29’755). Error bars 










 rs3798220 rs140570886 rs1652507 rs1800769 rs9458001 
rs3798220 0.01932745 0.703204 0.05355715  0.0273448 
rs140570886 0.703204 0.01551685 0.0759549  0.0393634 
rs1652507 0.05355715 0.0759549 0.1591815 0.965 0.0177401 
rs1800769   0.965  0.014 
rs9458001 0.0273448 0.0393634 0.0177401 0.014 0.2250345 
Table 1: Linkage Disequilibrium and Minor Allele frequency. This table shows the pairwise 
r2 measure of Linkage Disequilibrium (LD) between the reported SNPs and their respective 
minor allele frequency (MAF) in bold on the diagonal. Values in Italic were computed in the 
European sub-samples of the 1000 Genomes Project using the LDmatrix tool 
(https://ldlink.nci.nih.gov/) as rs1800769 was absent from the HRC imputation panel. Other 













1) CAD ~ covariates  342046 222021     NA 
2) CAD ~ rs140570886 + covariates 342045 221804 1 217.04 4×10-49 NA 
3) CAD ~ rs140570886 + rs9458005 + 
rs1652507 + covariates 
342043 221770 2 33.57 5.1×10-08 5.1×10-08 
4) CAD ~ rs140570886 + rs9458005 * 
rs1652507 +  covariates 
342042 221768 1 2.32 0.13 7.9×10-08 
5) CAD ~ rs140570886 * rs9458005 * 
rs1652507 +  covariates 
342039 221755 3 13.42 0.004 6.5×10-09 
6) CAD ~ rs140570886 * rs9458005 * 
rs1652507 +rs3798220+   
covariates 
342038 221753 1 1.93 0.16 8.2×10-09 
7) CAD ~ rs140570886 * rs9458005 * 
rs1652507 * rs3798220+   
covariates 
342031 221746 7 6.22 0.51 8.2×10-09 
Table 2: ANOVA Table reporting likelihood ratio test results for nested model in the 
model selection procedure. The table displays the result of a series of successive likelihood 
ratio test between a nested model of increasing complexity performed on the merged dataset 
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the Residual Deviance and degrees of freedom of from each row’s model. The “Df” and 
“Deviance” columns respectively report the difference in degrees of freedom and deviance 
between each row’s model and the model from the previous row. The “p-value” column reports 
the p-value of the likelihood ratio test between each row’s model and the previous one. The “P-
value LRT model 2” column reports the p-value of the likelihood ratio test between each model 
and the model containing only the additive effect of rs140570886 . The * operator denotes 
factor crossing: a*b is interpreted as a+b+a × b and a*b*c as a+b+c+ a × b + a × c + b × c. The 
10 multidimensional scaling components of the genetic variance and the study were included 
as covariates in every model. Tables showing the results of the same analysis with 3, 5 or 7 








no genetics M_null 222063.0 NA NA 
haplotypes M_haplo 221813.6 NA NA 
SNPs M_SNPs 221818.3 NA NA 
SNPs + interactions M_interact 221810.6 0.0034 NA 
haplotypes + SNPs +  
interactions 
M_full 221814.4 0.0268 0.262 
Table 3: Model selection using AIC and Likelihood ratio test confirms epistatic 
interactions at the LPA locus. This table displays the Akaike Information Criterion (AIC) and 
results of likelihood ratio test for nested models of increasing complexity performed on the 
merged dataset including the 10 CAD studies and the UK Biobank dataset. The “Comparison 
M_SNPs” and “Comparison M_interact” columns respectively report the p-values of the 
likelihood ratio tests with the M_SNPs and M_interact models as null model. The 10 
multidimensional scaling components of the genetic variance and were included as covariates 
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